'
Supriya
Lifescience hosted a conference call on Nov 13, 2025. During the call, the
company was represented by Dr. Satish Wagh, Executive Chairman & WTD; Dr.
Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial
Officer.
Key takeaways of the call
In Q2 FY26,
EBITDA margin improved supported by backward integration efforts.
Backward
integrated products, accounted for 78% of H1 FY26 revenue. The total number of
backward integrated products are 18.
Despite a muted
start in Q1 FY26, management reaffirmed its guidance of approximately 20% YoY
revenue growth for FY26 and aims to achieve Rs 1,000 crore in revenue by FY27,
with an EBITDA margin of 33–35%.
Growth is
expected to be driven by the introduction of new products and expansion into
newer therapies.
Management
expects stronger H2 FY26 compared to H1 FY26...
Pleaselogin & subscribe to view the full report.
More Reports
|
|